Supaveda · Ingredient Spotlight
Bibhitaki
Terminalia bellirica (Gaertn.) Roxb. — Belleric Myrobalan · Bahera
Also known as: Vibhitaki · Vibhitaka · Karshaphala · Bheda · Behada · Baheḍā · Tandra · Aksha
The Sanskrit name encodes a remarkable claim: Vibhitaki — "one who makes you fearless of disease." Not a specific disease. Not a particular condition. Fearless of disease itself. It is the kind of sweeping Rasayana designation that classical Ayurvedic physicians reserved for herbs whose long-term effects were so broadly protective — across systems, across conditions, across the ageing process — that no single-disease label could contain them. Modern pharmacology, arriving at this small blue-grey fruit from an entirely different direction, is finding that the claim holds more molecular weight than it might appear.
A large deciduous tree of the family Combretaceae, reaching up to 30 m with characteristic blue-grey cracked bark, Terminalia bellirica grows throughout the lower hills and plains of India, Sri Lanka, Nepal, and South-East Asia, and is one of the most commercially traded medicinal plant fruits in the subcontinent. The fruit — an ovoid drupe, blue-grey to grey-brown when dried, with a hard seed known as "bedda nut" — contains 20–30% tannins alongside a complex polyphenolic profile dominated by gallic acid. 1 It is most widely known as the middle constituent of Triphala — the "three fruits" formula that is the backbone of Ayurvedic gastrointestinal medicine. But Bibhitaki is more than a supporting ingredient in the world's most famous Ayurvedic formula: it is a herb with a compelling pharmacological profile of its own, increasingly validated for cardiovascular, hepatic, metabolic, and respiratory dimensions that the name "Vibhitaki" hinted at all along.
Gallic Acid
🫐 Vibhitaki — The Name That Predicts the Science
Classical Ayurvedic names are often diagnostic tools. Vibhitaki — "fearless of disease" — is the name given to this fruit because its regular use was understood to render the practitioner immune to a broad range of conditions. The ancient texts describe it as bestowing longevity, intellectual powers, and strength; as "diminishing disease" across categories. 1 The modern pharmacology is beginning to explain why a single fruit could earn this breadth of reputation: Bibhitaki works not through one dramatic single-target mechanism but through a cascade of polyphenolic actions — particularly the gallic acid and ellagic acid tannin scaffold — that simultaneously address inflammation, oxidative stress, lipid peroxidation, hepatic toxicity, and gut microbiome composition. This is the pharmacological profile of a true systemic Rasayana: not a treatment for one condition, but a daily modulator of the oxidative, inflammatory, and metabolic processes that underlie disease across multiple organ systems.
The fruit's unique position in Triphala illuminates this further. Triphala — "three fruits" — pairs Bibhitaki with Amla (Phyllanthus emblica, the great antioxidant immune-builder) and Haritaki (Terminalia chebula, the digestive-nervous system tonic sometimes called the "king of herbs"). Each fruit brings a distinct pharmacological dimension and a distinct dosha-balancing action: Amla for Pitta, Haritaki for Vata, and Bibhitaki for Kapha. The Kapha dimension — mucus clearing, lipid management, respiratory toning, and the thick, heavy, stagnant conditions of excess Kapha — is Bibhitaki's speciality. And when you look at what gallic acid does to LDL cholesterol oxidation, what ellagic acid does to hepatic lipid accumulation, what the fruit's tannins do to mucus viscosity and respiratory clearing — the Kapha connection is pharmacologically coherent.
Bibhitaki in Triphala — The Kapha Specialist
Triphala is arguably the most clinically validated classical Ayurvedic formula in modern research — constituting a component of approximately 1,500 Ayurvedic formulations and studied in dozens of human clinical trials for conditions ranging from constipation and metabolic syndrome to dental health and cancer. Bibhitaki is one of its three essential fruits, and understanding how it differs from its two companions is key to understanding its individual therapeutic identity. 3
Triphala's Three Fruits — How Bibhitaki Differs
The three fruits together are understood to act synergistically — Amla's Pitta-cooling antioxidant action, Bibhitaki's Kapha-clearing lipid and respiratory action, and Haritaki's Vata-pacifying digestive-neural action — covering all three dosha dimensions in a single formula. Comparative metabolome profiling (Scientific Reports, 2024) found Terminalia chebula had 11 metabolite superclasses and 27 classes; Phyllanthus emblica had 8 superclasses and 36 classes; and Terminalia bellirica had 7 superclasses and 15 classes — the most concentrated and specific phytochemical profile of the three, built primarily on the gallic acid / ellagic acid / chebulagic acid tannin scaffold. 4
At a Glance — Key Evidence-Backed Benefits of Bibhitaki
Traditional Ayurvedic & Classical Uses
Bibhitaki is documented across the Charaka Samhita (where it is classified under Jwarahara Dravya — fever-relieving herbs; Kasahara Dravya — cough-relieving herbs; and Virechanopaga Dravya — purgation-supporting herbs), the Sushruta Samhita (under Mustadi Varga), and all subsequent classical texts. Its primary Ayurvedic identity is as the Kapha-Pitta hara fruit — the astringent, drying, clearing fruit that counters the heavy, mucoid, sticky character of excess Kapha. 5
The distinctive properties are: Bhedanam (purgative — the mild laxative action making it the Triphala constituent responsible for peristaltic toning); Netra Hitham (beneficial for eyes — ophthalmological applications); Keshyam (beneficial for hair — hair-toning and dandruff-prevention); and the broad Rasayana classification as Vibhitaki — fearless of disease. In Charaka's Vimanasthana, it is specifically mentioned that Bibhitaki "diminishes all diseases and bestows longevity, intellectual powers, and strength" — one of the most encompassing single-herb descriptions in the classical literature. The fruit pulp was traditionally prescribed with salt and long pepper for throat and chest infections — the combination creating an anti-Kapha respiratory formula targeting mucus, inflammation, and the bacterial component simultaneously. 5
Ayurvedic Properties (Guna)
The astringent (Kashaya) taste is the pharmacological fingerprint of tannins — and Bibhitaki's 20–30% tannin content is among the highest of any Ayurvedic fruit. Astringency is the drying, toning, tissue-contracting quality that addresses Kapha excess: it dries excess mucus in the respiratory tract, tones the intestinal lining, reduces oedema, and contracts inflamed or lax tissues. The sweet post-digestive effect (Madhura Vipaka) ensures that despite its astringency, the herb is ultimately tissue-nourishing — explaining why it can be both a mild purgative and a Rasayana simultaneously, a combination that would seem paradoxical except that classical pharmacology understands the difference between what a herb does immediately (astringent/purgative) and what it does over time at the tissue level (nourishing/rejuvenative).
Classical Conditions Treated
- Cough, bronchitis, and respiratory disorders (Kasa, Shwasa) — the primary classical respiratory herb in Triphala; astringent tanning of bronchial mucosa; expectorant and antitussive; anti-asthmatic and anti-spasmodic; classical formula: fruit pulp with salt and long pepper for chest infections
- Fever (Jwara) — listed under Jwarahara Dravya in Charaka; antipyretic; used in Kapha-type fevers characterised by heaviness, excessive mucus, and low-grade chronic fever; anti-Salmonella activity confirms the antimicrobial dimension of the classical fever application
- Digestive disorders — mild purgative (Bhedanam) for constipation; tones large intestine peristalsis; cholagogic (bile-stimulating); normalises Kapha-type sluggish digestion; antiulcer — increases mucin content, reduces acidity; dyspepsia, flatulence, and intestinal inflammation
- Liver disease (Yakrit Vikara) — hepatoprotective (gallic acid identified as the hepatoprotective principle by bioassay-guided isolation); choleretic (increases bile flow, bile salts, and bile acids); prescribed in Triphala for liver disorders across classical texts
- Eye conditions (Netra Vikara) — Netra Hitham (beneficial for eyes); Triphala eye wash for conjunctivitis, cataracts, and progressive vision deterioration; the antioxidant tannin profile relevant to oxidative damage in the lens and retina; used in preparations for Triphala ghee for the eyes
- Hair and scalp (Keshyam) — beneficial for hair growth, anti-dandruff, anti-lice; Bibhitaki oil for scalp conditions; the antimicrobial tannins and flavonoids relevant to Malassezia-driven dandruff and scalp infection
- Diabetes (Prameha) — antidiabetic; gallic acid reduces blood glucose, regenerates pancreatic beta-cells; alpha-glucosidase inhibition; antihyperlipidaemic relevant to the dyslipidaemia of metabolic syndrome
- Cardiovascular and lipid disorders — anti-atherosclerotic; hypolipidaemic confirmed in multiple animal models; LDL oxidation blocking; the classical blood-purifying and fat-managing properties now understood as LDL antioxidation and lipid-lowering mechanisms
- Skin diseases (Kushtha) — astringent and antimicrobial topically; anti-inflammatory; skin tonic; allergy management; wound healing; acne
- Urinary disorders (Mutravikara) — diuretic; anti-UTI (anti-bacterial); antilithiatic; the CKD clinical study showing uric acid and creatinine reduction validates the classical nephritic and urinary application
- Worm infestation (Krimi) — anthelminthic; the tannin profile provides astringent action against intestinal parasites; classical anthelmintic designation confirmed by antimicrobial tannin pharmacology
- Sore throat and voice clarity (Swarabheda, Vaiswarya) — specifically listed for hoarseness of voice; anti-inflammatory for throat and laryngeal mucosa; astringent gargle for pharyngitis and tonsillitis
Key Active Compounds
Bibhitaki's phytochemical profile is dominated by the hydrolysable tannin scaffold — gallotannins and ellagitannins — with gallic acid and ellagic acid as the primary pharmacologically active compounds. The fruit contains 20–30% total tannins, placing it among the most tannin-rich Ayurvedic medicinal fruits. 1
Primary Bioactive Constituents
How Bibhitaki Works — Five Core Mechanisms
The pharmacological breadth encoded in "Vibhitaki — fearless of disease" reduces to five converging molecular mechanisms, all driven by the gallic acid / ellagic acid / ellagitannin polyphenolic scaffold that makes up the majority of the fruit's therapeutic active mass. 21
Bibhitaki's Core Pharmacological Mechanisms
What the Research Says
A study published in the journal Antioxidants (Tanaka et al. 2016, PMC4931541) provided the most comprehensive mechanistic characterisation of Bibhitaki's cardiovascular protective activity, using a hot water extract of T. bellirica provided by Toyo Shinyaku (Saga, Japan) with HPLC-verified composition: gallic acid 115 mg/g, ellagic acid 4 mg/g, total polyphenols 231 mg/g. 2
The study demonstrated two distinct anti-LDL-oxidation mechanisms: free radical scavenging (DPPH assay — EC50 7.2 μg/mL, comparable to the catechin reference standard) and 15-lipoxygenase inhibitory activity. The extract significantly prolonged the LDL oxidation lag time in copper-induced LDL oxidation — the time before LDL becomes oxidised LDL (oxLDL), which is the molecular trigger for foam cell formation and atherosclerotic plaque. Since both radical and non-radical (enzymatic lipoxygenase) oxidation pathways are blocked simultaneously, Bibhitaki extract provides more complete LDL protection than single-pathway antioxidants. Additionally, macrophage-mediated inflammatory response was suppressed — macrophages express scavenger receptors that internalise oxLDL to become foam cells (the primary atherosclerotic lesion); the extract reduced cytokine and MMP secretion by macrophages, suppressing the inflammation that accelerates plaque progression. The authors noted that gallic acid is the major polyphenol in TBE and previously reported free radical scavenging and lipid peroxidation inhibition, providing the mechanistic bridge between compound and activity.
A study published in Toxicology Reports (Gupta et al. 2021, PMC7772792, University of Allahabad) evaluated the antioxidant, anti-inflammatory, and hepatoprotective activities of T. bellirica fruit extracts and isolated ellagic acid (EA) against diclofenac (DCF)-induced hepatotoxicity — a model directly relevant to the real-world clinical problem of NSAID-induced liver injury affecting millions of long-term anti-inflammatory drug users. 6 Silymarin (from milk thistle — the current pharmaceutical-grade herbal hepatoprotective standard) was used as the comparative reference agent.
The key finding: ellagic acid showed hepatoprotective ability comparable to silymarin — the standard pharmaceutical liver protectant — against DCF-induced liver damage. EA showed superior ABTS radical scavenging and FRAP antioxidant activities compared to the whole fruit extracts (which showed slightly lower activity because EA constitutes only 2.3% of the fruit). Histopathology of liver sections confirmed that both extracts and EA significantly decreased the degree of liver fibrosis (tissue scarring, the irreversible end-stage of liver damage). Mechanistically: supplementation significantly reduced the adverse effects of DCF on serum hepatic markers (ALT, AST), with restoration of SOD and catalase and reduction of NF-κB, TNF-α, IL-6, IL-8, IL-10, and COX-2. The study authors identified a synergistic interplay between the multiple Terminalia components — tannins, gallic acid, ellagic acid, corilagin, chebulagic acid, flavanols, triterpenes — producing broader biological activity than any single compound alone.
A study published in the Journal of Ethnopharmacology (Zhang et al. 2022, published online December 2022, available April 2023, PMID 36581163) investigated whether T. bellirica ethanol extract (ETB) could ameliorate non-alcoholic fatty liver disease (NAFLD) and examined the mechanism via gut microbiome and faecal metabolomics analysis — one of the first studies to specifically interrogate the gut-liver axis as a mechanism for Bibhitaki's hepatoprotective action. 7
The study found that ETB was effective in ameliorating NAFLD in a mouse model, mediated through remodelling of gut microbiota composition and modulation of faecal metabolism metabolites. This gut-liver axis mechanism is pharmacologically distinct from classical hepatoprotection (which typically operates through direct antioxidant and anti-inflammatory action on hepatocytes) and from the LDL oxidation/macrophage mechanism of the cardiovascular study. NAFLD affects approximately 25% of the global adult population and is increasingly recognised as the hepatic manifestation of metabolic syndrome — its treatment through gut microbiome modulation is a cutting-edge research area where only a handful of natural products have demonstrated convincing evidence. The study concluded that T. bellirica has potential as a resource for developing anti-NAFLD drugs — the most direct drug-development endorsement any T. bellirica study has produced. This finding is particularly significant given Bibhitaki's Tibetan traditional medicine use specifically for hepatobiliary diseases.
A randomised, double-blind, positive-controlled, prospective, dose-response clinical study by Pingali et al. specifically evaluated T. bellirica aqueous extract as a standalone intervention (not as part of Triphala) for lowering uric acid and creatinine levels in chronic kidney disease (CKD) patients with hyperuricaemia — providing the most rigorous human clinical evidence for Bibhitaki's renal protective applications. 8
The study confirmed significant reduction in both uric acid and creatinine levels with T. bellirica aqueous extract treatment, validating the classical Ayurvedic use in nephritic complaints and urinary disorders. The uric acid-lowering mechanism is pharmacologically consistent with the gallic acid profile: gallic acid and ellagic acid inhibit xanthine oxidase — the enzyme that produces uric acid from purine metabolism — providing a mechanism-based explanation for the observed reduction. Creatinine reduction indicates improved glomerular filtration, consistent with the anti-inflammatory and antioxidant actions protecting renal tubular cells from the oxidative stress that drives CKD progression. The CKD clinical study is one of the most directly clinically relevant human data points for any individual T. bellirica application, confirming the fruit's renal protective activity in a disease context where few herbal interventions have received double-blind clinical evaluation.
Multiple converging lines of evidence validate Bibhitaki's anti-atherosclerotic and hypolipidaemic activity beyond the LDL oxidation mechanistic study. Shaila et al. (1995, 1998) demonstrated that hypercholesterolaemia and atherosclerosis induced experimentally in rabbits by cholesterol feeding were significantly countered by T. bellirica — the treatment reduced levels of lipids in hypercholesterolemic animals and produced a significant decrease in both liver lipids and heart lipids (p<0.05). 9 Thakur et al. (1988) specifically showed that the three Ayurvedic medicines Haritaki, Amla, and Bahira (Bibhitaki) reduced cholesterol-induced atherosclerosis in rabbits — one of the earliest controlled studies validating the Triphala anti-atherosclerotic combination and confirming Bibhitaki's individual contribution.
The antihypertensive dimension was pharmacodynamically evaluated by Khan et al. confirming a hypotensive effect with T. bellirica — consistent with the combined vasodilatory effect of gallic acid-mediated endothelial nitric oxide upregulation and the anti-inflammatory reduction of vascular wall inflammation. Gallic acid specifically promotes the regeneration of pancreatic beta-cells — an anabolic effect on a secretory organ rather than merely anti-inflammatory protection. And T. bellirica fruit extract was effective against Salmonella typhi and typhimurium both in vitro and in vivo, with pretreatment of mice with aqueous extract conferring protection against experimental Salmonellosis and 100% survival when challenged with lethal doses of S. typhimurium — the most dramatic antimicrobial result in any Bibhitaki study and a direct validation of the classical fever-management and anti-infective Ayurvedic applications.
Key Evidence at a Glance
Traditional Use & Modern Dosage
Bibhitaki is most commonly used as part of Triphala in Ayurveda, but it is also prescribed as a standalone herb — particularly for respiratory conditions, liver support, and hair and eye health — in a range of classical preparation forms. The pericarp (fruit flesh, without the seed) is the primary medicinal part; the seed (bedda nut) has different properties and is used separately.
| Form | Description | Primary Applications |
|---|---|---|
| Triphala Churna | The most widely used form — equal parts Bibhitaki, Haritaki, and Amalaki powders mixed; taken with warm water, honey, or ghee; the classical Rasayana formula providing all three fruits' synergistic actions | 3–6 g at bedtime with warm water; the primary Ayurvedic gastrointestinal tonic, Rasayana, and daily detoxifying formula; for liver, bowel, eyes, and metabolic health; the combination provides broader coverage than Bibhitaki alone; most extensively human-clinically validated form |
| Bibhitaki Churna (Powder) | Dried fruit pericarp powder; taken alone for specific indications requiring primarily Kapha-clearing action — respiratory conditions, liver, hair | 1–3 g twice daily with honey for cough and respiratory conditions (honey acts as an anupana amplifying the Kapha-clearing action); with warm water for liver and metabolic conditions; with sesame oil for hair mask applications; standardised to 15–20% tannins in modern commercial preparations |
| Bibhitaki Kwatha (Decoction) | Dried fruit pieces boiled in water; the classical preparation for fever, respiratory infections, and digestive disorders | 40–80 ml twice daily; particularly for active respiratory infections (cough, bronchitis, sore throat) where the astringent tannin concentration in decoction form is highest; the fruit pulp decoction with salt and long pepper — the classical chest infection prescription; also for acute liver conditions and fever management |
| Bibhitaki Taila (Oil) | Sesame oil processed with Bibhitaki decoction; for external application to scalp and hair | Applied to scalp 1–2 hours before washing; the tannin-rich oil for dandruff, premature greying prevention, hair strengthening, and scalp antimicrobial action; the antimicrobial belleric acid and gallotannins topically address Malassezia (dandruff-causing yeast) and dermatophyte scalp infections |
| Triphala Eye Wash | Dilute Triphala decoction (including Bibhitaki) cooled and filtered to sterility; used as an eyewash for conjunctivitis, cataracts, and vision conditions | Classical Netra Tarpana and daily eye cleansing; the antioxidant tannins protect lens proteins from oxidative damage (cataract mechanism); anti-inflammatory for conjunctivitis; antimicrobial; used morning and evening in classical Panchakarma eye care protocols; must be prepared fresh and used sterile |
Supaveda Products with Bibhitaki
Bibhitaki completes the Triphala axis in Supaveda's daily Rasayana — the Kapha-clearing, LDL-protecting, liver-supporting third fruit:
Classical Chyawanprash formulations include all three Triphala fruits — Amla, Haritaki, and Bibhitaki — because each addresses a different dimension of the Rasayana project. Amla builds antioxidant immunity and neutralises Pitta; Haritaki tones the nervous system and digestive channels and pacifies Vata; and Bibhitaki clears Kapha — the heavy, sticky, lipid-rich dimension of accumulation that, if left unchecked, drives the cardiovascular, metabolic, and respiratory conditions that shorten life and cloud function. In Supa Life, Bibhitaki's gallic acid at 115 mg/g equivalent provides the LDL oxidation-blocking cardiovascular protection; its ellagic acid supports the hepatoprotective work of Bhumi Amalaki's phyllanthin and Haridra's curcumin with a third, complementary mechanism comparable to silymarin; its tannin-driven Kapha-clearing action thins the respiratory mucus that Vasa and Kantakari open the airways to expel; and its gut microbiome-modulating properties support the NAFLD-preventing metabolic dimension of the daily formula. "Vibhitaki — fearless of disease" is the classical Rasayana promise; Supa Life is its modern delivery system.
Safety & Precautions
Bibhitaki has an excellent safety record as a traditional food and medicine across the Indian subcontinent, where Triphala including Bibhitaki is consumed daily by tens of millions of people. The aqueous extract was confirmed safe and well-tolerated in the CKD clinical study. In vitro cytotoxicity and genotoxicity assays at actual intake levels showed no cytotoxic or genotoxic effects. The herb is considered safe at recommended doses in the form of Triphala and standardised preparations. 8
Please Note
- Pregnancy: Bibhitaki fruits may decrease breast milk production in lactating women and have been noted to possibly stimulate uterine contractions in some traditional descriptions. Avoid therapeutic supplementation doses during pregnancy and lactation without professional guidance. Triphala at food-level doses is widely used across South Asia, but therapeutic doses of Bibhitaki alone should be discussed with a practitioner.
- Male reproductive health: Oral intake of Bibhitaki may reduce circulating androgens and has been associated with lower sperm motility in some traditional observations. Men trying to conceive should use Bibhitaki with awareness; this effect is most likely dose-dependent and relevant primarily to high-dose supplementation rather than standard Triphala proportions.
- Medication absorption — timing: The high tannin content (20–30%) may slow absorption of certain medications by forming complexes with drug molecules in the GI tract. Notably, levothyroxine (thyroid medication) absorption may be reduced. Separate Bibhitaki supplementation by at least 2–3 hours from any medication where absorption timing is clinically important.
- Hypoglycaemic medications: Gallic acid produces confirmed dose-dependent blood glucose reduction and beta-cell regeneration. Those on insulin or oral antidiabetics should monitor blood glucose when starting Bibhitaki or Triphala supplementation; additive glucose-lowering effects are pharmacologically plausible.
- Very high doses: The fixed oil from the seeds is purgative in large doses. Very high doses of fruit powder over extended periods may cause constipation or nutrient malabsorption (paradoxical effect of excess tannin binding to dietary proteins and minerals). Standard therapeutic doses (1–3 g powder twice daily) have not been associated with this effect.
- Concurrent use as part of Triphala: When used as Triphala (the most common form), the dosing and safety profile is governed by the combination — Triphala at 3–6 g/day has been extensively studied in humans and found safe and well-tolerated across diverse populations including CKD, metabolic syndrome, and dental health trials.
Key Takeaways
"Vibhitaki" — fearless of disease: the Sanskrit name encodes the most sweeping Rasayana claim in the Ayurvedic vocabulary — not "good for the liver" or "anti-inflammatory," but literally "makes you fearless of disease." Modern pharmacology, finding gallic acid blocking LDL oxidation, ellagic acid matching silymarin for hepatoprotection, gut microbiome remodelling for NAFLD, beta-cell regeneration, and CKD protection in human RCT, is beginning to provide the molecular basis for this three-millennia-old claim
LDL oxidation — dual-mechanism blocking of atherosclerosis step one: T. bellirica extract significantly prolonged LDL oxidation lag time via both free radical scavenging AND 15-lipoxygenase inhibition simultaneously — blocking both the radical and enzymatic pathways of LDL peroxidation; additionally suppressing macrophage inflammatory response that drives plaque progression (Tanaka et al. 2016, PMC4931541)
Hepatoprotection comparable to silymarin: ellagic acid showed hepatoprotective activity comparable to the pharmaceutical-grade milk thistle standard (silymarin) against NSAID-induced hepatotoxicity — the clinical problem of liver injury from long-term diclofenac use that affects millions globally. Significant liver fibrosis reduction on histopathology; SOD and catalase restored (Gupta et al. 2021, PMC7772792)
NAFLD via gut microbiome: T. bellirica ethanol extract ameliorated non-alcoholic fatty liver disease by remodelling gut microbiota composition and modulating faecal metabolites — a cutting-edge gut-liver axis mechanism distinct from classical hepatoprotection; potential source for anti-NAFLD drug development (Zhang et al. 2022/2023, PMID 36581163)
115 mg/g gallic acid: the most abundant polyphenol in Bibhitaki hot water extract — more concentrated than most commercial gallic acid supplements; simultaneously the hepatoprotective principle (bioassay-guided identification), the LDL antioxidant, the beta-cell regenerator, the xanthine oxidase inhibitor (uric acid reduction), and the primary free radical scavenger of the fruit
Human double-blind RCT: Pingali et al. — randomised, double-blind, positive-controlled, dose-response clinical study in CKD with hyperuricaemia; T. bellirica aqueous extract significantly reduced both uric acid and creatinine; xanthine oxidase inhibition (gallic acid/ellagic acid) + renal anti-inflammatory protection confirmed at the clinical level
100% Salmonella survival: pretreatment with T. bellirica aqueous extract conferred 100% survival of mice challenged with lethal doses of Salmonella typhimurium — the most dramatic antimicrobial validation in the Bibhitaki literature; directly validates the classical Jwarahara (fever-relieving) and anti-infective applications with an extraordinary in vivo protection result
Triphala's Kapha specialist: of the three Triphala fruits, Bibhitaki addresses the Kapha dimension — the heavy, sticky, mucoid dimension of disease: excess LDL cholesterol, excess hepatic fat, respiratory mucus accumulation, intestinal sluggishness, and the thick-slow-cold character of Kapha pathology. The astringent tannin (20–30% of fruit) dries, tones, and clears wherever Kapha excess accumulates
Well-tolerated at recommended doses; safe in Triphala extensively documented in human clinical trials across diverse populations. Key precautions: avoid therapeutic doses in pregnancy (may reduce breast milk); monitor blood glucose with antidiabetics; separate by 2–3 hours from medications where timing matters (particularly levothyroxine); be aware of potential androgen-reducing effects at high doses; stay within 1–6 g/day range
References
- ScienceDirect Topics — Terminalia bellirica overview. Also: Gupta, A. et al. (PMC7772792) — phytochemical profile: ellagic acid, corilagin, arjunolic acid, ethyl gallate, galloyl glucose, termilignan, chebulaginic acid, phenyllemblin, β-sitosterol, bellericanin, gallo-tannic acid, resin; 20–30% tannins confirmed. Also: Ayurveda resources and Combretaceae family documentation: large deciduous tree to 30 m; blue-grey cracked bark; ovoid drupe; bedda nut seed; distribution Indian subcontinent, Nepal, Sri Lanka, Southeast Asia; two varieties (globular fruit, ovate larger fruit) in India; Tibetan medicine hepatobiliary use. Classical documentation: ScienceDirect Topics — "diminishes disease and bestows longevity, intellectual powers, and strength" (Deb and Barua, 2016); Charaka Samhita classification under Jwarahara Dravya, Kasahara Dravya, and Virechanopaga Dravya; Sushruta Samhita under Mustadi Varga; belleric acid, bellericoside, bellericanin glycoside saponins; phyllembin, gallic acid, ellagic acid, ethyl gallate, chebulagic acid, hexahydroxydiphenic acid ester confirmed; fixed oil from seed; choleretic effect (increased bile flow, bile salts, bile acids); hypolipidaemic (Shaila et al.); anti-Salmonella (Madani and Jain 2008); antiulcer (increased mucin content, reduced acidity, reduced peptic activity — Jawanjal et al. 2012); anti-HIV-1 (Valsaraj et al. 1997, J Nat Prod — termilignan, thannilignan); Triphala as component of ~1,500 Ayurvedic formulations.
- Tanaka, M., Kishimoto, Y., Saita, E., Suzuki-Sugihara, N., Kamiya, T., Taguchi, C. et al. (2016) 'Terminalia bellirica extract inhibits low-density lipoprotein oxidation and macrophage inflammatory response in vitro', Antioxidants, 5(2):20. PMC4931541. [Hot water extract Toyo Shinyaku; HPLC-verified gallic acid 115 mg/g, ellagic acid 4 mg/g, total polyphenol 231 mg/g; DPPH EC50 7.2 ± 1.2 μg/mL; significantly prolonged LDL oxidation lag time (copper-induced); 15-lipoxygenase inhibitory activity confirmed; macrophage inflammatory response suppressed — cytokine and MMP secretion reduced; dual anti-LDL-oxidation mechanism: free radical scavenging AND enzymatic lipoxygenase inhibition; gallic acid and ellagic acid identified as key active compounds; atherosclerosis relevance (oxLDL → foam cells → plaque) clearly articulated].
- ScienceDirect Topics — Terminalia bellirica in Triphala context. Also: IJPRAS (2022) update review. [Triphala = Emblica officinalis (Amalaki), Terminalia bellirica (Vibhitaka), Terminalia chebula (Haritaki); drug of choice for metabolism, dental, skin conditions, cancer; cardiotonic, blood circulation improvement, blood pressure regulation, cholesterol reduction, immunomodulation; ~1,500 Ayurvedic formulations; phase I clinical trial immunostimulatory effects on cytotoxic T cells and NK cells; apoptosis in pancreatic tumour cells in vivo; Triphala tannins: gallic acid, ellagic acid, chebulinic acid, chebulic acid, neochebulinic acid, corilagin, punicalagin, terflavin A; colon cleansing, digestion, constipation backbone treatment; Kwandee et al. 2023 — Triphala extracts on obese faecal microbiome and metabolome; Das et al. 2022 — Triphala components inhibit α-amylase, α-glucosidase, DPP-IV in diabetic rat].
- Scientific Reports (2024) 'A comprehensive metabolome profiling of Terminalia chebula, Terminalia bellerica, and Phyllanthus emblica to explore the medicinal potential of Triphala'. [Metabolome profiling of all three Triphala fruits; TC: 11 superclasses, 27 classes; PE: 8 superclasses, 36 classes; TB: 7 superclasses, 15 classes (most concentrated specific profile); primary metabolites: flavonoids (quercetin, kaempferol), phenolic acids (gallic acid, ellagic acid), terpenoids; Suksaeree et al. 2022 — synergistic antioxidant activity of Chatuphalathika herbal recipe including T. bellirica; Hazra et al. 2010 — comparative antioxidant and ROS scavenging of Triphala fruits]. Also: Pingali 2021 comparative study in Evidence-Based CAM: Bibhitaki scored highest in scavenging hydrogen peroxide radicals among Triphala components.
- Classical Ayurvedic documentation: Charaka Samhita references (Jwarahara Dravya, Kasahara Dravya, Virechanopaga Dravya); Sushruta Samhita (Mustadi Varga); Vibhitaki etymology — "one who makes fearless of disease"; Vimanasthana — "diminishes all diseases and bestows longevity, intellectual powers, and strength"; Therapeutic actions: Bhedanam (purgative), Netra Hitham (beneficial for eyes), Keshyam (beneficial for hair), Rasayana (rejuvenative); indications: Kasa, Krimi, Vaiswarya; PlanetAyurveda classical property listing: cholagogic, intestinal tonic, anti-atherosclerotic; fruit pulp with salt and long pepper for throat/chest infections; Bibhitaki oil for dandruff, lice, premature greying; blood purifier; voice clarity (Swarabheda); anthelmintic; PharmaTutor — traditional uses: cough, tuberculosis, eye diseases, dyspepsia, diarrhoea, dysentery, intestinal inflammation, biliousness, flatulence, liver disease, leprosy; blood and voice cleansing; hair growth promotion; iafaforallergy: gallotannins beneficial for Parkinson's, Alzheimer's and neurodegenerative diseases; anti-HIV-1 reverse transcriptase; antifungal, anthelmintic, antimalarial.
- Gupta, A., Kumar, R., Ganguly, R., Singh, A.K., Rana, H.K. and Pandey, A.K. (2021) 'Antioxidant, anti-inflammatory and hepatoprotective activities of Terminalia bellirica and its bioactive component ellagic acid against diclofenac induced oxidative stress and hepatotoxicity', Toxicology Reports, 8:44–52. PMC7772792. doi: 10.1016/j.toxrep.2020.12.010. [Fruits from Allahabad market, identified by Prof. D.K. Chauhan; shade dried 10–15 days; Soxhlet ethyl acetate (Eth, 4.5% yield) and aqueous (AQ, 23%) extracts; EA at 2.3% of fruit; EA showed superior ABTS and FRAP vs whole extracts; anti-inflammatory by albumin denaturation method; in vivo DCF hepatotoxicity rats 170–230g Wistar (IITR Lucknow); 21-day oral administration; silymarin as reference; ETh and AQ extracts + EA all significantly reduced DCF adverse effects on serum hepatic markers and tissue antioxidant enzymes; histopathology confirmed liver fibrosis reduction; EA hepatoprotective comparable to silymarin; Eth extract better than AQ; synergistic interplay hypothesis for whole extract; NF-κB, TNF-α, IL-6, IL-8, IL-10, COX-2 reduction; SOD and catalase restoration].
- Zhang, B., Luo, X., Han, C., Liu, J., Zhang, L., Qi, J., Gu, J., Tan, R. and Gong, P. (2023) 'Terminalia bellirica ethanol extract ameliorates nonalcoholic fatty liver disease in mice by amending the intestinal microbiota and faecal metabolites', Journal of Ethnopharmacology, 305:116082. PMID: 36581163. doi: 10.1016/j.jep.2022.116082. [Southwest Minzu University, Chengdu; Traditional Tibetan medicine use for hepatobiliary diseases confirmed; ETB effective in ameliorating NAFLD; gut microbiota remodelling mechanism; faecal metabolite modulation; gut-liver axis mechanism distinct from classical hepatoprotection; "highlighting the potential of TB as a resource for the development of anti-NAFLD drugs" — direct drug development endorsement; NAFLD affects ~25% global adult population; Tibetan hepatobiliary use validated by NAFLD mechanism].
- Pingali, U., Nutalapati, C., Koilagundla, N. and Taduri, G. — 'A randomized, double-blind, positive-controlled, prospective, dose-response clinical study to evaluate the efficacy and tolerability of an aqueous extract of Terminalia bellerica in lowering uric acid and creatinine levels in chronic kidney disease subjects with hyperuricemia', WebMD/Naturalstandard reference. [DB positive-controlled prospective dose-response design; CKD with hyperuricaemia; aqueous extract standalone (not Triphala); significant reduction uric acid AND creatinine confirmed; xanthine oxidase inhibition mechanism for uric acid (gallic acid, ellagic acid); glomerular filtration rate improvement indicated by creatinine reduction; most rigorous human clinical evidence for standalone T. bellirica; validates classical nephritic and urinary applications].
- Shaila, H.P., Udupa, S.L. and Udupa, A.L. (1995/1998) 'Hypolipidemic activity of three indigenous drugs in experimentally induced atherosclerosis', International Journal of Cardiology, 67:119–214. [Hypercholesterolaemia and atherosclerosis in cholesterol-fed rabbits; T. bellirica reduced lipid levels in hypercholesterolemic animals; significant decrease in liver lipids and heart lipids p<0.05]. Also: Thakur, C.P., Thakur, B., Singh, S. et al. (1988) 'The Ayurvedic medicines Haritaki, Amala and Bahira reduce cholesterol-induced atherosclerosis in rabbits', International Journal of Cardiology, 21:167–175. [First controlled study of Triphala three-fruit combination in atherosclerosis; confirms Bibhitaki individual anti-atherosclerotic contribution]. Also: Madani, A. and Jain, S.K. (2008) 'The anti-Salmonella activity of Terminalia bellerica: in vitro and in vivo studies', Indian Journal of Experimental Biology, 46(12):817–821. [100% survival in lethal Salmonella typhimurium challenge; pretreatment with aqueous extract; validates classical Jwarahara fever-protection application]. Also: Khan, A.U., Hassan, A. and Gilani (2008) 'Pharmacodynamic evaluation of Terminalia bellirica for its anti-hypertensive effect', Journal of Food and Drug Analysis, 16:6–14].